- Home
- Publications
- Publication Search
- Publication Details
Title
Breast cancer: an up‐to‐date review and future perspectives
Authors
Keywords
-
Journal
Cancer Communications
Volume 42, Issue 10, Pages 913-936
Publisher
Wiley
Online
2022-09-09
DOI
10.1002/cac2.12358
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
- (2022) Erica L. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
- (2022) Min Yan et al. LANCET ONCOLOGY
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
- (2022) Rosie Bradley et al. LANCET ONCOLOGY
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- (2022) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
- (2022) Yue Chai et al. Journal of Personalized Medicine
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
- (2022) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
- (2022) Melanie Royce et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
- (2022) Anne Jacobson ONCOLOGIST
- Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
- (2022) Anne Jacobson ONCOLOGIST
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- A Population-Based Study of Genes Previously Implicated in Breast Cancer
- (2021) Chunling Hu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women
- (2021) et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2021) Binghe Xu et al. LANCET ONCOLOGY
- Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)
- (2021) Aditya Bardia et al. CLINICAL CANCER RESEARCH
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
- (2021) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer
- (2021) Sibylle Loibl et al. LANCET
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
- (2021) Hope S Rugo et al. LANCET ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
- (2021) Sara A. Hurvitz et al. ONCOLOGIST
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
- (2021) H.J. Burstein et al. ANNALS OF ONCOLOGY
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
- (2021) Yuanyuan Zhang et al. CANCER CELL
- Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
- (2021) Xin Hua et al. CLINICAL CANCER RESEARCH
- Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
- (2021) Binghe Xu et al. NATURE MEDICINE
- Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
- (2021) F. Poggio et al. ANNALS OF ONCOLOGY
- The 2019 WHO classification of tumours of the breast
- (2020) Puay Hoon Tan et al. HISTOPATHOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Could a Personalized Strategy Using Accelerated Partial Breast Irradiation be an Advantage for Elderly Patients? A Systematic Review of the Literature and Multidisciplinary Opinion
- (2020) Luca Tagliaferri et al. Journal of Oncology
- Partial-breast irradiation versus whole-breast radiotherapy for early breast cancer: A systematic review and update meta-analysis
- (2020) Gustavo Arruda Viani et al. Brachytherapy
- Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
- (2020) Junjie Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
- (2020) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
- (2020) Adrian Murray Brunt et al. LANCET
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer
- (2020) Esther Pohl-Rescigno et al. JAMA Oncology
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
- (2020) Binghe Xu et al. BREAST CANCER RESEARCH AND TREATMENT
- Endocrine Therapy in Early Breast Cancer
- (2020) Katja Krauss et al. Breast Care
- Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
- (2020) Yi-Zhou Jiang et al. CELL RESEARCH
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer
- (2020) Gerd Fastner et al. RADIOTHERAPY AND ONCOLOGY
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
- (2020) Ke-Da Yu et al. JAMA Oncology
- Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
- (2020) Arlene Chan et al. Clinical Breast Cancer
- Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
- (2020) Sabrina Kahler-Ribeiro-Fontana et al. EJSO
- Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial
- (2020) Icro Meattini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Adjuvant Capecitabine in Triple-Negative Breast Cancer
- (2020) Heather A. Parsons et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
- (2020) Xi Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum
- (2020) Rebecca Dent et al. LANCET ONCOLOGY
- Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
- (2020) B. Xu et al. ANNALS OF ONCOLOGY
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review of clinical outcomes and radiotherapy-associated toxicity in multicatheter accelerated partial breast irradiation
- (2019) Yang Lv et al. MEDICINE
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2019) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis
- (2019) Yasmin Korzets et al. BREAST CANCER RESEARCH AND TREATMENT
- Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
- (2019) Peng Yuan et al. EUROPEAN JOURNAL OF CANCER
- West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
- (2019) Ulrike Nitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2019) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
- (2019) Andrea DeCensi et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Zefei Jiang et al. LANCET ONCOLOGY
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
- (2019) J M S Bartlett et al. ANNALS OF ONCOLOGY
- Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients
- (2019) Yifan Wu et al. BREAST CANCER RESEARCH AND TREATMENT
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
- (2019) Sara A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
- (2019) Olivia Pagani et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
- (2019) Ana Lluch et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
- (2019) Jack Cuzick et al. LANCET
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- (2019) Jennifer J Gao et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
- (2018) F Poggio et al. ANNALS OF ONCOLOGY
- The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial
- (2018) Kari M. Rosenkranz et al. ANNALS OF SURGICAL ONCOLOGY
- Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
- (2018) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
- (2018) Marco Colleoni et al. LANCET ONCOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
- (2018) Ivana Sestak et al. JAMA Oncology
- First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
- (2018) Mothaffar Rimawi et al. JOURNAL OF CLINICAL ONCOLOGY
- Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
- (2018) Viviana Galimberti et al. LANCET ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study
- (2018) Jean-Marc Classe et al. BREAST CANCER RESEARCH AND TREATMENT
- Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer
- (2018) S. R. Tee et al. BRITISH JOURNAL OF SURGERY
- Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study
- (2018) Marissa C. van Maaren et al. INTERNATIONAL JOURNAL OF CANCER
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
- (2018) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
- (2018) Thomas Ruhstaller et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Eleftherios P Mamounas et al. LANCET ONCOLOGY
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
- (2017) M.J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
- (2017) Armando E. Giuliano et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2017) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
- (2017) Joanne L. Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
- (2017) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
- (2017) Charlotte E Coles et al. LANCET
- Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
- (2017) Pin Zhang et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
- (2017) Vivianne C G Tjan-Heijnen et al. LANCET ONCOLOGY
- Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial
- (2017) Csaba Polgár et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ki67 assessment in breast cancer: an update
- (2017) Frederique Penault-Llorca et al. PATHOLOGY
- Screening for breast cancer
- (2017) Kimberly S. Peairs et al. SEMINARS IN ONCOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- The Role of MRI in Breast Cancer Screening
- (2017) Constance D. Lehman et al. Journal of the National Comprehensive Cancer Network
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy
- (2016) Judy C. Boughey et al. ANNALS OF SURGERY
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
- (2016) Mehra Golshan et al. BREAST CANCER RESEARCH AND TREATMENT
- Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence
- (2016) Tong Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials
- (2016) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
- (2016) Abigail S. Caudle et al. JOURNAL OF CLINICAL ONCOLOGY
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis
- (2016) Chong Geng et al. PLoS One
- Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial
- (2016) A. Murray Brunt et al. RADIOTHERAPY AND ONCOLOGY
- Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates
- (2015) Mehra Golshan et al. ANNALS OF SURGERY
- Incidence and Time Path of Lymphedema in Sentinel Node Negative Breast Cancer Patients: A Systematic Review
- (2015) Nick Gebruers et al. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
- Breast Cancer Screening for Women at Average Risk
- (2015) Kevin C. Oeffinger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
- (2015) Jean-Francois Boileau et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
- (2015) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- (2015) Claudia Allemani et al. LANCET
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- (2015) Sara M. Tolaney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regional Nodal Irradiation in Early-Stage Breast Cancer
- (2015) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
- (2014) Reshma Jagsi et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
- (2014) Mila Donker et al. LANCET ONCOLOGY
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- (2014) Olivia Pagani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer
- (2013) Zachary S. Zumsteg et al. ANNALS OF SURGICAL ONCOLOGY
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
- (2013) Judy C. Boughey JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prospective Study of the Efficacy of Breast Magnetic Resonance Imaging and Mammographic Screening in Survivors of Hodgkin Lymphoma
- (2013) Andrea K. Ng et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
- (2013) Dennis C. Sgroi et al. JNCI-Journal of the National Cancer Institute
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
- (2013) Jack Cuzick et al. LANCET
- The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
- (2013) Joanne S Haviland et al. LANCET ONCOLOGY
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
- (2013) Thorsten Kuehn et al. LANCET ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis
- (2011) Veronique K.M. Tan et al. JOURNAL OF SURGICAL ONCOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- ASCO-CAP Guidelines for Breast Predictive Factor Testing
- (2011) M. Elizabeth Hale Hammond APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
- (2010) V. G. Vogel et al. Cancer Prevention Research
- Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study)
- (2010) Francesco Sardanelli et al. INVESTIGATIVE RADIOLOGY
- Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
- (2010) Christiane Kuhl et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings
- (2008) Eleftherios P. Mamounas ANNALS OF SURGICAL ONCOLOGY
- Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
- (2008) Wendie A. Berg JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
- (2008) M. J. Ellis et al. JNCI-Journal of the National Cancer Institute
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- (2008) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic Accuracy of Digital versus Film Mammography: Exploratory Analysis of Selected Population Subgroups in DMIST
- (2008) Etta D. Pisano et al. RADIOLOGY
- Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld?
- (2008) Mariella Mannino et al. RADIOTHERAPY AND ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started